Get the Stockscreener App
9.46
0.94%
-0.09
Novavax Inc stock is traded at $9.46, with a volume of 5.00M.
It is down -0.94% in the last 24 hours and up +27.84% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.
See More
Previous Close:
$9.55
Open:
$9.59
24h Volume:
5.00M
Relative Volume:
0.83
Market Cap:
$1.54B
Revenue:
$1.08B
Net Income/Loss:
$422.82M
P/E Ratio:
4.1491
EPS:
2.28
Net Cash Flow:
$-637.33M
1W Performance:
+10.64%
1M Performance:
+27.84%
6M Performance:
+68.93%
1Y Performance:
-34.40%
1-Day Range:
$9.24
$9.75
1-Week Range:
$8.32
$9.75
52-Week Range:
$5.01
$14.70
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
9.46 | 1.55B | 1.08B | 422.82M | -637.33M | 2.28 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.30 | 104.83B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
600.00 | 63.59B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.35 | 60.43B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
ARGX
Argen X Se Adr
|
800.00 | 48.45B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
343.87 | 37.91B | 4.56B | -176.77M | 225.30M | -1.7177 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-28-25 | Resumed | H.C. Wainwright | Buy |
| Aug-20-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-17-25 | Initiated | Citigroup | Sell |
| Feb-28-25 | Initiated | BTIG Research | Buy |
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
A Fresh Look at Novavax (NVAX) Valuation After Recent Share Price Rebound - Yahoo Finance
Smart tools for monitoring Novavax Inc.’s price actionRate Hike & Fast Momentum Stock Entry Tips - newser.com
Analyzing recovery setups for Novavax Inc. investorsJuly 2025 Update & Real-Time Chart Pattern Alerts - newser.com
Is Novavax Inc. (NVV1) stock a buy on weaknessCEO Change & Momentum Based Trading Signals - newser.com
Is Novavax Inc. stock attractive after correctionQuarterly Investment Review & Weekly Watchlist of Top Performers - newser.com
Using Bollinger Bands to evaluate Novavax Inc.2025 Price Momentum & AI Enhanced Trading Alerts - newser.com
Will Novavax Inc. (NVV1) stock benefit from sector leadership2025 Trading Volume Trends & Free Safe Entry Trade Signal Reports - newser.com
Is Novavax Inc. stock attractive for retirement portfoliosPortfolio Gains Summary & Daily Growth Stock Investment Tips - newser.com
Novavax Inc. (NVAX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Noteworthy Wednesday Option Activity: ONON, NVAX, COMM - Nasdaq
Novavax’s Vaccine Milestone and Market Movement - StocksToTrade
Will Novavax Inc. stock benefit from AI adoptionInsider Selling & Precise Buy Zone Tips - newser.com
Will Novavax Inc. outperform the market2025 Valuation Update & Precise Buy Zone Identification - newser.com
Novavax expands Sanofi partnership for pandemic flu vaccine development By Investing.com - Investing.com Nigeria
Novavax (NVAX) Expands License for Matrix-M with Sanofi - GuruFocus
Novavax (NVAX) Exceeds Market Returns: Some Facts to Consider - sharewise.com
Novavax Deepens Partnership with Sanofi: Matrix-M Adjuvant Set to Bolster Pandemic Influenza Vaccine Development - BBN Times
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - MSN
Novavax Amends Deal With Sanofi, Broadens Partnership - Stocktwits
Novavax allows Sanofi to use Matrix-M adjuvant for pandemic flu candidate - Seeking Alpha
Novavax expands Sanofi partnership for pandemic flu vaccine development - Investing.com
Novavax Announces Progress on Sanofi Agreement - PR Newswire
Novavax falls after guidance cut on lower vaccine sales - MSN
What analysts say about Novavax Inc NVV1 stockPrice Momentum Alerts & Breakout Stock Alerts - earlytimes.in
Ask Axios: Where to find a Novavax shot in Ohio - Axios
Can Novavax Inc. rally from current levels2025 Market Sentiment & AI Optimized Trade Strategies - newser.com
What analysts say about Novavax Inc stockMarket Sentiment Indicators & Superior Growth Trading - earlytimes.in
Novavax Inc Stock Analysis and ForecastMarket Sentiment Report & The Smart Money Is Buying These Picks - earlytimes.in
Here's Why Novavax (NVAX) is a Strong Momentum Stock - sharewise.com
Robert F. Kennedy Jr. Faces Impeachment Push From Haley Stevens Over 'Health Care Chaos' And Rising Costs: 'Enough Is Enough' - Benzinga
Here is What to Know Beyond Why Novavax, Inc. (NVAX) is a Trending Stock - sharewise.com
Novavax, Inc. (NASDAQ:NVAX) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Citi Initiates Coverage of Novavax (NVAX) With a Sell Rating - MSN
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.68%
0.38%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):